508 / 1031
Bartelink H, Lancet Oncol 2015; 16:47‐56
Follow up: 20y
N = 4.318
≤40a
41‐50a
Age
Gain (LR)
≤40
11.6%
41-50
5.9%
51-60
2.9%
51‐60a
>60a
>60
3%
|
|
508 / 1031
Bartelink H, Lancet Oncol 2015; 16:47‐56
Follow up: 20y
N = 4.318
≤40a
41‐50a
Age
Gain (LR)
≤40
11.6%
41-50
5.9%
51-60
2.9%
51‐60a
>60a
>60
3%